A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. - Wikidata - awgldk - TriplyDB

A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease.

A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease.

http://www.wikidata.org/entity/Q50870630

about

Endoscopic scoring indices for evaluation of disease activity in Crohn’s disease Optimal delivery of follow-up care after surgery for Crohn's disease: current perspectives Relevance of fecal calprotectin and lactoferrin in the post-operative management of inflammatory bowel diseases Fecal calprotectin in inflammatory bowel disease Faecal calprotectin: Management in inflammatory bowel disease Disease monitoring in inflammatory bowel disease Clinicians' guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease Fecal Calprotectin Measured By Patients at Home Using Smartphones--A New Clinical Tool in Monitoring Patients with Inflammatory Bowel Disease.Predictors of recurrence of Crohn's disease after ileocolectomy: a review.Faecal calprotectin levels differentiate intestinal from pulmonary tuberculosis: An observational study from Southern India.The role and utility of faecal markers in inflammatory bowel disease.Are faecal markers good indicators of mucosal healing in inflammatory bowel disease?Rapid fecal calprotectin testing to assess for endoscopic disease activity in inflammatory bowel disease: A diagnostic cohort study The use of fecal calprotectin as a biomarker in gastrointestinal disease.Fecal biomarkers in the diagnosis and monitoring of Crohn's disease.Diagnosis and monitoring of postoperative recurrence in Crohn's disease.The clinical value of faecal calprotectin and lactoferrin measurement in postoperative Crohn's disease.C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis.Clinical Utility of Biomarkers in IBD.Luminally expressed gastrointestinal biomarkers.Monitoring and detection of disease recurrence after resection for Crohn's disease: the role of non-invasive fecal biomarkers.Mining the fecal proteome: from biomarkers to personalised medicine.Fecal biomarkers in inflammatory bowel disease: how, when and why?Utility of Biomarkers in the Management of Inflammatory Bowel Disease.Impact of disease location on fecal calprotectin levels in Crohn's disease.Fecal calprotectin for evaluating postoperative recurrence of Crohn's disease: a meta-analysis of prospective studies.Optimizing post-operative Crohn's disease treatment.Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists.Risk factors for postoperative recurrence of Crohn's disease with emphasis on surgical predictors.Correlation of 18F-FDG PET/MRE Metrics with Inflammatory Biomarkers in Patients with Crohn's Disease: A Pilot Study.Fecal Calprotectin More Accurately Predicts Endoscopic Remission of Crohn's Disease than Serological Biomarkers Evaluated Using Balloon-assisted Enteroscopy.Influence of Diet on the Course of Inflammatory Bowel Disease.Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays.Faecal calprotectin and magnetic resonance imaging in detecting Crohn's disease endoscopic postoperative recurrence.Fecal Calprotectin Levels Are Closely Correlated with the Absence of Relevant Mucosal Lesions in Postoperative Crohn's Disease.Letter: Limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease.Rapid faecal tests for detecting disease activity in colonic inflammatory bowel disease.Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure.The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease.Correlation Between Calprotectin and Modified Rutgeerts Score.

P2860

Q26470550-6BA9855E-C27C-421C-A4D3-516AB10B3B12 Q26740356-12E3A923-4574-446E-8012-FC878E6CED41 Q26750230-A0F1942D-B92D-4FB1-8559-B4C156614968 Q26766527-1923FC5D-71F9-4B1A-9024-A7D18ECD89F4 Q26776145-2C5E24F2-E79B-416A-BCE8-39E08C4DE9A4 Q26777553-6ECB388F-B8F1-411C-9FED-D3B9842915B4 Q28080934-D8CD089A-6806-4AC7-8CD7-1A53978A1199 Q33445756-2195C590-6832-4830-97AA-615EF96A8813 Q34366947-8B6A97C6-9034-4299-9166-3130DCA141DF Q34418883-C3D97E17-2427-45BE-91C7-679B74B1770B Q34456258-397390D4-BC68-4029-91C9-737FD9CC8BD0 Q36193147-0DA59C30-1B03-487B-954D-609A42B2CEE3 Q36449604-FBEA1020-AAD5-4555-94C7-124D7AC9F197 Q38171862-FABD5CA4-4BF4-4F5F-8D59-29A5607E4655 Q38219444-2E2C41A1-4DD5-4C27-95D4-810B9C83A5F5 Q38230312-966F88B4-74EF-49F3-A8A3-8EC016D26507 Q38344883-60E2E1B4-7A2A-43BB-B539-60F0F3CF0651 Q38474301-56A5F4F6-BA62-4BF6-8BA3-8CB36E34C66C Q38539968-B92B8286-2F4E-4A74-A109-9E4763A87B30 Q38636313-3018B727-09CA-48DA-B685-4CFD322B4B30 Q38657630-8B755609-289F-4754-85B7-E9AAA3EB000C Q38865393-DFDB1B31-5EEA-4A2D-824F-2750DF542B1C Q38918650-5B86F249-D2FC-4C2A-BCC3-A309BA4975B8 Q39110763-4B3A0C47-B254-45DA-AE7F-5E0945CC102A Q41504176-792E59DC-AA13-481A-859C-6AA9AD6415F7 Q41608430-8B406601-CD4E-4C35-B3D8-E8CD534F7AC7 Q42934164-796F1DB2-3C53-49A5-B29C-5309F401EF5A Q44405203-4A78BD16-F1E0-4730-BA3B-88B6C12B2135 Q47155734-705B07B6-7EDB-4175-836C-55FCE878FBE2 Q47156789-0F9085FB-A85F-41F6-809B-B959EE4FF5EB Q47940693-A5B4CDBB-75CC-42E1-BD6F-4F70475C9B19 Q48367753-24EFAE80-525A-482D-A32F-CDF09A57D780 Q49126220-9162397B-7E0D-459D-856D-D8AABC480320 Q49446241-0E0EE998-1775-4587-88F4-F3A2AA9BFC16 Q50224534-CB75C0BD-3B7B-452C-8EDF-F37505166F0B Q50469584-D9010513-8F74-4E74-A97E-FA7F4523816C Q50859208-60275C3C-7EDE-461C-BAFA-CC76F28BE2BA Q51618737-65DA07C3-82B3-4295-9BAF-1FB0C841D074 Q52676637-F63EBBC6-DE58-44AE-9A48-52076B5F5DE8 Q52983772-7111F8D6-B360-474C-B066-558299E01EFA

P2860

A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease.

http://www.wikidata.org/entity/Q50870630

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

A new rapid test for fecal cal ...... recurrence in Crohn's disease.

@en

A new rapid test for fecal cal ...... recurrence in Crohn's disease.

@nl

type

label

A new rapid test for fecal cal ...... recurrence in Crohn's disease.

@en

A new rapid test for fecal cal ...... recurrence in Crohn's disease.

@nl

prefLabel

A new rapid test for fecal cal ...... recurrence in Crohn's disease.

@en

A new rapid test for fecal cal ...... recurrence in Crohn's disease.

@nl

P1433

Q50870630-04F14685-309C-4EAF-B2AF-90F2DD8D08EC

P1476

Q50870630-F8E243D5-0DD1-4776-B6B1-01C6F1771C72

P2093

Q50870630-4C7F90C5-0A68-4D95-8F29-F4B58A1DBD47

Q50870630-56E787D0-4D8D-4579-95CF-1224A28C5A06

Q50870630-CEED1088-54E1-4D2E-8451-964BA4F69DF8

Q50870630-D9DEBD7A-66A1-45EE-9137-9BDC8B7DE46D

P2860

Q50870630-069B63E5-8F23-4B3C-B1BA-B542DFB54A78

Q50870630-072B6E64-9DB0-44B5-951F-0895063CAFF6

Q50870630-0B48E44E-B74B-4ACE-A3DF-98CC1DB02A44

Q50870630-0EC187AE-36E4-4377-A014-5869F4B846B5

Q50870630-170C7B99-93BE-467E-9E66-9C9E615AFD1E

Q50870630-1DD5B96A-CBEE-4E79-B9B1-94B55CE75392

Q50870630-20237045-E866-4E77-8DB5-45DB136867C2

Q50870630-2F106E50-6C10-4230-B3CF-B555F0DA01B5

Q50870630-332F1C42-BDCF-4C15-904C-398213679D5D

Q50870630-42C55F6A-991F-47C7-B730-A55FC1AF2710

P304

Q50870630-EF09BEB6-9F3E-40F8-9222-4D48E3D41602

P31

Q50870630-D3C02BC4-F710-459C-B14F-A0F36FD7E7F7

P356

Q50870630-F56FE48E-88D4-45A5-B13F-42243FD6DCC2

P433

Q50870630-B8D1940A-78F5-4F79-87B2-B2D381F3A2A7

P478

Q50870630-B4CDF37E-BC47-4CBD-9235-D15BEC62F096

P50

Q50870630-7D80FD19-1A99-485B-B309-205CE92A226C

Q50870630-EB0676B3-6993-4CE2-B0D4-513CDA37868B

P577

Q50870630-1F883541-5396-498F-AD94-EEBC8AA33A68

P5875

Q50870630-AA6251A9-6AD2-4F1D-855B-D9F232932561

P698

Q50870630-6FAA58FB-E767-4C41-985A-C1FE00B36536

P921

Q50870630-CFFF86E4-C695-43BC-86AD-0C0782C82319

P356

J.CROHNS.2013.05.005

P1433

Journal of Crohn's and Colitis

P1476

A new rapid test for fecal cal ...... recurrence in Crohn's disease

@en

P2093

Alexandra Ruiz

http://www.w3.org/2001/XMLSchema#string

Alicia López-García

http://www.w3.org/2001/XMLSchema#string

Lorena Rodríguez

http://www.w3.org/2001/XMLSchema#string

Triana Lobatón

http://www.w3.org/2001/XMLSchema#string

P2860

A simple method for assessing intestinal inflammation in Crohn's disease

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations.

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.

Role of faecal calprotectin as non-invasive marker of intestinal inflammation.

Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestiv

Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease.

Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients.

Laboratory markers in IBD: useful, magic, or unnecessary toys?

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol

Clinical implications of mucosal healing for the management of IBD.

P304

e641-51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CROHNS.2013.05.005

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Jordi Guardiola

Francisco Rodríguez Moranta

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

243966178

http://www.w3.org/2001/XMLSchema#string

P698

23810085

http://www.w3.org/2001/XMLSchema#string

P921